854 related articles for article (PubMed ID: 26194981)
1. Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy.
Kumar V; Ramachandran R; Kumar A; Nada R; Suri D; Gupta A; Kohli HS; Gupta KL; Jha V
Nephrology (Carlton); 2015 Aug; 20(8):572-5. PubMed ID: 26194981
[TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy.
Hoxha E; Kneißler U; Stege G; Zahner G; Thiele I; Panzer U; Harendza S; Helmchen UM; Stahl RA
Kidney Int; 2012 Oct; 82(7):797-804. PubMed ID: 22673885
[TBL] [Abstract][Full Text] [Related]
3. PLA2R and membranous nephropathy: A 3 year prospective Australian study.
Hill PA; McRae JL; Dwyer KM
Nephrology (Carlton); 2016 May; 21(5):397-403. PubMed ID: 26369693
[TBL] [Abstract][Full Text] [Related]
4. Membranous nephropathy: integrating basic science into improved clinical management.
Cattran DC; Brenchley PE
Kidney Int; 2017 Mar; 91(3):566-574. PubMed ID: 28065518
[TBL] [Abstract][Full Text] [Related]
5. Circulating antibodies to α-enolase and phospholipase A
Kimura Y; Miura N; Debiec H; Morita H; Yamada H; Banno S; Ronco P; Imai H
Clin Exp Nephrol; 2017 Feb; 21(1):117-126. PubMed ID: 26830547
[TBL] [Abstract][Full Text] [Related]
6. Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China.
Guo N; Cao Y; Dai H; Yuan L; Shi L; Zhang Y
Med Sci Monit; 2019 Dec; 25():9364-9368. PubMed ID: 31813930
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Histological Features of Phospholipase A2 Receptor-Associated and Thrombospondin Type-I Domain-containing 7A-Associated Idiopathic Membranous Nephropathy: A Single Center Retrospective Study from China.
Zhang D; Zou J; Zhang C; Zhang W; Lin F; Jiang G
Med Sci Monit; 2018 Jul; 24():5076-5083. PubMed ID: 30032157
[TBL] [Abstract][Full Text] [Related]
8. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).
Radice A; Trezzi B; Maggiore U; Pregnolato F; Stellato T; Napodano P; Rolla D; Pesce G; D'Amico M; Santoro D; Londrino F; Ravera F; Ortisi G; Sinico RA
Autoimmun Rev; 2016 Feb; 15(2):146-54. PubMed ID: 26527329
[TBL] [Abstract][Full Text] [Related]
9. Primary membranous nephropathy in adolescence: A prospective study.
Kumar V; Varma AK; Nada R; Ghosh R; Suri D; Gupta A; Kumar V; Rathi M; Kohli H; Jha V; Gupta K; Ramachandran R
Nephrology (Carlton); 2017 Sep; 22(9):678-683. PubMed ID: 27334445
[TBL] [Abstract][Full Text] [Related]
10. [The relationship between anti-phospholipase A2 receptor antibody and idiopathic membranous nephropathy].
Lin W; Li H; Li X; Qin Y; Su Y; Yu Y; Guan Y; Duan L; Li Y; Wen Y; Li X
Zhonghua Nei Ke Za Zhi; 2015 Sep; 54(9):783-8. PubMed ID: 26674797
[TBL] [Abstract][Full Text] [Related]
11. [Anti-phospholipase A2 receptor (anti-PLA2R) antibodies and idiopathic membranous nephropathy: which role in diagnosis and prognosis of this disease?].
Netti GS; Ranieri E
G Ital Nefrol; 2014; 31(3):. PubMed ID: 25030016
[TBL] [Abstract][Full Text] [Related]
12. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis.
Dai H; Zhang H; He Y
Sci Rep; 2015 Mar; 5():8803. PubMed ID: 25740009
[TBL] [Abstract][Full Text] [Related]
14. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.
Kanigicherla D; Gummadova J; McKenzie EA; Roberts SA; Harris S; Nikam M; Poulton K; McWilliam L; Short CD; Venning M; Brenchley PE
Kidney Int; 2013 May; 83(5):940-8. PubMed ID: 23364522
[TBL] [Abstract][Full Text] [Related]
15. The relationship of anti-phospholipase A2 receptor antibody and C5a complement with disease activity and short-term outcome in idiopathic membranous nephropathy.
Chi JN; Lai TS; Wu CF; Fu TY; Chou YH; Chiu YL; Lin WC; Chiang WC; Chen YM; Wu MS
J Formos Med Assoc; 2019 May; 118(5):898-906. PubMed ID: 30639075
[TBL] [Abstract][Full Text] [Related]
16. M-type phospholipase A
Kanda S; Horita S; Yanagihara T; Shimizu A; Hattori M
Pediatr Nephrol; 2017 Apr; 32(4):713-717. PubMed ID: 27921164
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.
Radice A; Pieruzzi F; Trezzi B; Ghiggeri G; Napodano P; D'Amico M; Stellato T; Brugnano R; Ravera F; Rolla D; Pesce G; Giovenzana ME; Londrino F; Cantaluppi V; Pregnolato F; Volpi A; Rombolà G; Moroni G; Ortisi G; Sinico RA
J Nephrol; 2018 Apr; 31(2):271-278. PubMed ID: 29081027
[TBL] [Abstract][Full Text] [Related]
18. [Preliminary results of research on a new marker of idiopathic membranous nephropathy: anti-PLA2R].
Kozioł M; Sikora A; Kozioł-Montewka M; Smarz-Widelska I; Orłowska-Kowalik G; Pyszna W; Załuska W; Ksiazek A
Pol Merkur Lekarski; 2014 Mar; 36(213):171-4. PubMed ID: 24779214
[TBL] [Abstract][Full Text] [Related]
19. Relationship between the status of phospholipase A2 receptor and prognosis of idiopathic membranous nephropathy.
Li YQ; Liu ZZ; Lin KX; Liu RH; Ni L; Liu GX; Lan HY; Shi YJ
Nephrology (Carlton); 2020 Feb; 25(2):144-149. PubMed ID: 31226230
[TBL] [Abstract][Full Text] [Related]
20. Comparison of measurements of anti-PLA2R antibodies in Japanese patients with membranous nephropathy using in-house and commercial ELISA.
Kaga H; Komatsuda A; Yamamoto S; Kikuchi T; Kamata M; Sato A; Odaka M; Yokota SI; Takahashi N; Wakui H
Clin Exp Nephrol; 2019 Apr; 23(4):465-473. PubMed ID: 30756249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
